BioCentury

8:00 AM GMT, Nov 3, 2008
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Emerging Company Profile

Cardoz: Anti-inflammatory synergy

Over the past decade, it's become clear that atherosclerosis is a chronic inflammatory disease to which inflammatory cells, in particular mast cells, are major contributors. Based on this shift in the understanding of disease pathology, Cardoz AB believes its combination products targeting the inflammatory components of atherosclerosis and lipoproteins may provide benefit over current treatments.

Cardoz's

Read the full 550 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.